Abstract:Background: Current influenza vaccines need to be annually reformulated to well match the predicated circulating strains. Thus, it is critical for developing a novel universal influenza vaccine that would be able to confer cross-protection against constantly emerging divergent influenza virus strains. Influenza virus A is a genus of the Orthomyxoviridae family of viruses. Influenza virus nucleoprotein (NP) is a structural protein which encapsidates the negative strand viral RNA, and anti-NP antibodies play role in cross-protective immunity. Lactococcus lactis (L. lactis) is an ideal vaccine delivery vehicle via oral administration route. However, L. lactis vectored vaccine exhibits poor immunogenicity without the use of mucosal adjuvant. To enhance the immunogenicity of L. lactis vectored vaccine, cholera toxin B (CTB) subunit, one of mucosal adjuvants, is a safe adjuvant for oral route, when combined with L. lactis vectored vaccine. In this study, we hypothesized that pNZ8008, a L. lactis expression plasmid, encoding NP antigen, would be able to elicit cross-protection with the use of CTB via oral administration route. Results: To construct L. lactis vectored vaccine, nucleoprotein (NP) gene of A/California/04/2009(H1N1) was sub-cloned into a L. lactis expression plasmid, pNZ8008. The expression of recombinant L. lactis/pNZ8008-NP was confirmed by Western blot, immunofluorescence assay and flow cytometric analysis. Further, immunogenicity of L. lactis/pNZ8008-NP alone or adjuvanted with cholera toxin B (CTB) subunit was evaluated in a mouse model via oral administration route. Antibodies responses were detected by ELISA. The result indicated that oral administration of L. lactis/pNZ8008-NP adjuvanted with CTB could elicit significant humoral and mucosal immune responses, as well as cellular immune response, compared with L. lactis/pNZ8008-NP alone. To further assess the cross-protective immunity of L. lactis/pNZ8008-NP adjuvanted with CTB, we used L. lactis/pNZ8110-pgsA-HA1 alone or adjuvanted with CTB as controls. Mice that received L. lactis/pNZ8008-NP adjuvanted with CTB were completely protected from homologous H1N1 virus and showed 80% protection against heterologous H3N2 or H5N1 virus, respectively. By contrast, L. lactis/pNZ8110-pgsA-HA1 adjuvanted with CTB also conferred 100% protection against H5N1 virus infection, but indicated no cross-protection against H1N1 or H5N1 virus challenge. As controls, mice vaccinated orally with L. lactis/pNZ8008-NP alone or L. lactis/pNZ8110-pgsA-HA1 alone could not survive. Conclusion: This study is the first to report the construction of recombinant L. lactis/pNZ8008-NP and investigate its immunogenicity with the use of CTB. Compared with L. lactis/pNZ8110-pgsA-HA1 adjuvanted with CTB, our data support 5 × 10(11) CFU of L. lactis/pNZ8008-NP adjuvanted with 1 µg of CTB is a better combination for universal influenza vaccines development that would provide cross-protective immunity against divergent influenza A viruses.

Exposed N-terminus of Chemokine LTN is Important for Its Mucosal Adjuvant Effects

Modulation of Immunogenicity and Immunoprotection of Mucosal Vaccine Against Coxsackievirus B3 by Optimizing the Coadministration Mode of Lymphotactin Adjuvant

IL-17 As a Molecular Adjuvant on Enhancing Cellular Immune Responses to HIV DNA Vaccination

Enhancement of the mucosal immune responses and prophylactic effect of a novel coxsackievirus B3-specific mucosal DNA vaccine by co-administration of lymphotactin

Mechanism of Enhanced Viral-Myocarditis-prophylactic Effect of a Novel Coxsackievirus B3 Mucosal Vaccine by LTN Adjuvant

Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct.

Fusion-expressed CTB Improves Both Systemic and Mucosal T-cell Responses Elicited by an Intranasal DNA Priming/intramuscular Recombinant Vaccinia Boosting Regimen.

N-terminus of flagellin enhances vaccine efficacy against Actinobacillus pleuropneumoniae

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

Enhanced Resistance to Coxsackievirus B3-Induced Myocarditis by Intranasal Co-Immunization of Lymphotactin Gene Encapsulated in Chitosan Particle

In Vivo Characterization of Chimeric PCV DNA Clones Containing Heterogeneous Capsid Protein Nuclear Localization Signals (NLS).

Determination of fbe mucosal immunoadjuvantivity of recombinant EschericMa cott LTKA63 mutant and LTB

Production of Promising Heat-Labile Enterotoxin (LT) B Subunit-Based Self-Assembled Bioconjugate Nanovaccines against Infectious Diseases

[Fusion expression of Neisseria gonorrhoeae outmembrane protein with a mucosal adjuvant].

The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity

Cholera toxin B subunit acts as a potent systemic adjuvant for HIV-1 DNA vaccination intramuscularly in mice

The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT

As a Genetic Adjuvant, CTA Improves the Immunogenicity of DNA Vaccines in an ADP-ribosyltransferase Activity- and IL-6-dependent Manner.

Lymphotactin Gene-Modified Bone Marrow Dendritic Cells Act As More Potent Adjuvants for Peptide Delivery to Induce Specific Antitumor Immunity

The Adjuvant Double Mutant Escherichia coli Heat Labile Toxin Enhances IL-17A Production in Human T Cells Specific for Bacterial Vaccine Antigens

Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice